This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Novel Therapies in the Treatment of Cancer: The Emerging Role of Immunotherapies

Novel Therapies in the Treatment of Cancer: The Emerging Role of Immunotherapies

Format

Slide Lecture Series

Time to Complete

1.50 hours

Released

May 25, 2018

Expires

May 25, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Pharmacy Credits

Pharmacists may earn 1.50 CPE Credits (0.15 CEUs) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on ASHP.org and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck

Program Description

This educational activity will explore the growing role of immunotherapy in treating patients with both hematologic and solid tumor malignancies. Approvals for novel indications as well as place in therapy and association with biomarkers predictive of response will be discussed. Patient cases will be utilized to highlight therapy selection as well as common adverse effects. Specific focus will also include toxicity management strategies.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of cancer patients with immunotherapies.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Evaluate the current and future places in therapy for immunotherapy agents, including novel indications in both hematologic and solid tumor malignancies.
  • Identify common toxicities associated with immunotherapy and recommend best practices for their management.
  • Apply strategies for the appropriate selection of immunotherapy in patient scenarios, including consideration of biomarkers and unique patient characteristics.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships. In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.

Faculty

Christine M. Walko, PharmD, BCOP, FCCP, Activity Chair
Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Associate Professor
University of South Florida Morsani College of Medicine
Tampa, FL

Dr. Walko discloses the following:
Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board

Ragini R. Kudchadkar, MD
Associate Professor
Winship Cancer Institute of Emory University
Associate Director Hematology/Oncology Fellowship Program
Atlanta, GA

Dr. Kudchadkar discloses the following:
Bristol-Myers Squibb: Advisory Board member
Merck: Research funding received

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Instructions

In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact elearning@ashp.org.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue